Gut microbiota are related to Parkinson's disease and clinical phenotype
By F. Scheperjans, V. Aho, P. Pereira, K. Koskinen, L. Paulin, E. Pekkonen, E. Haapaniemi, S. Kaakkola, J. Eerola‐Rautio, Marjatta Pohja and 3 more. Movement Disorders, 2015
1,785 citations recorded by the source corpus.
In the course of Parkinson's disease (PD), the enteric nervous system (ENS) and parasympathetic nerves are amongst the structures earliest and most frequently affected by alpha‐synuclein pathology. Accordingly, gastrointestinal dysfunction, in particular constipation, is an important non‐motor symptom in PD and often precedes the onset of motor symptoms by years. Recent research has shown that intestinal microbiota interact with the autonomic and central nervous system via diverse pathways including the ENS and vagal nerve. The gut microbiome in PD has not been previously investigated. We compared the fecal microbiomes of 72 PD patients and 72 control subjects by pyrosequencing the V1–V3 regions of the bacterial 16S ribosomal RNA gene. Associations between clinical parameters and microbiota were analyzed using generalized linear models, taking into account potential confounders. On average, the abundance of Prevotellaceae in feces of PD patients was reduced by 77.6% as compared with controls. Relative abundance of Prevotellaceae of 6.5% or less had 86.1% sensitivity and 38.9% specificity for PD. A logistic regression classifier based on the abundance of four bacterial families and the severity of constipation identified PD patients with 66.7% sensitivity and 90.3% specificity. The relative abundance of Enterobacteriaceae was positively associated with the severity of postural instability and gait difficulty. These findings suggest that the intestinal microbiome is altered in PD and is related to motor phenotype. Further studies are warranted to elucidate the temporal and causal relationships between gut microbiota and PD and the suitability of the microbiome as a biomarker. © 2014 International Parkinson and Movement Disorder Society
Subfields: Gastroenterology, Molecular Biology, Speech and Hearing
View Paper: https://www.semanticscholar.org/paper/3ace4c9fc77d86e06ef8464e633682fc6f1e1b6f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Gastroenterology
In Molecular Biology
Citations in the corpus
- Microbiota in health and diseases (2022, result): “Oral microbiome is another key contributor to the development of neurological disorders, as improper maintenance of oral health can influence the growth of complex communities on the surface of teeth, tongue, or under the gum.280 Hicks et al. has reported that salivary microbiome analysis has shown ”
- Colonic bacterial composition in Parkinson's disease (2015, result): “There is one other report demonstrating changes in fecal microbiota composition in PD patients, which showed a decrease in the family Prevotellaceae in fecal samples.(73) We did not observe a significant decrease in the abundance of Prevotellaceae in our fecal analyses; however, the trend was the sa”
- The Gut Microbiota and Alzheimer’s Disease (2017, neutral): “Dysbiosis and alterations of the intestinal microbiota composition contribute to the development and progression of many diseases in humans, including inflammatory bowel disease (for review, see [15, 16]), type 2 diabetes mellitus (T2DM) [17, 18], obesity (for review, see [19, 20]), cardiovascular di”
- Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. (2016, background): “The most pronounced difference was observed in the reduction of Prevotellaceae family and subsequently in the Prevotella genus, previously found to be decreased in Parkinson's disease patients (Gustafsson et al., 2015; Scheperjans et al., 2015).”
- Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. (2016, background): “showed an association between the abundance of certain gut microbiota and PD [14,15]: amongst others, bacteria that have the capacity to produce short chain fatty acids (SCFA) were reduced in PD.”
- Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. (2018, background): “Moreover, a direct correlation between the abundance of Enterobacteriaceae and severity of postural instability and gait difficulty has been found in PD patients (Scheperjans et al., 2015).”
- Parkinson’s Disease and PD Medications Have Distinct Signatures of the Gut Microbiome (2017, background): “A prior study of PD has linked COMT inhibitors to altered abundance of some taxa.(11) Moreover, COMT inhibitors(33) and anticholinergics(34) have gastrointestinal side effects, which may be related to a dysbiosis of the microbiome.”
- Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis (2019, background): “Severity of symptoms, including postural instability and gait abnormality, is associated with alterations in the abundance of certain species of Enterobacteriaceae [164, 165].”
- Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. (2017, background): “In PD patients, changes in the GMB composition have been recently observed (Scheperjans et al., 2015; Keshavarzian et al., 2015; Hasegawa et al., 2015), and also, as alterations in the gut barrier function, membrane permeability, and inflammatory mediators production have been reported as affecting…”